Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]

Affiliations

• ¹ Royal Marsden Hospital, London and Surrey, United Kingdom. Electronic address: [email protected].
• ² Allgemeines Krankenhaus Wien, Vienna and Klinkum Klagenfurt am Wörthersee, Klagenfurt, Austria.
• ³ Hospital Jean Minjoz, Besançon, France.
• ⁴ Universitätsklinikum Magdeburg, Magdeburg, Germany.
• ⁵ Hôpital La Timone, Aix-Marseille University, Marseille, France.
• ⁶ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
• ⁷ Asan Medical Center, Seoul, Republic of Korea.
• ⁸ National Cheng Kung University Hospital, Tainan, Taiwan.
• ⁹ Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
• ¹⁰ The University of Hong Kong, Hong Kong.
• ¹¹ Istituto Oncologico Veneto IRCCS, Padova, Italy.
• ¹² Hepato-Gastroenterology and Digestive Oncology Unit, Centre Medico-chirurgical Magellan, CHU Bordeaux, France.
• ¹³ Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
• ¹⁴ Sutter Health California Pacific Medical Center, San Francisco, CA, USA.
• ¹⁵ National Cancer Center Hospital, Tokyo, Japan.
• ¹⁶ Eli Lilly and Company, Indianapolis, IN, USA.
• ¹⁷ Eli Lilly and Company, Bridgewater, NJ, USA.
• ¹⁸ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.